These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11959565)

  • 1. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.
    Tremblay CL; Giguel F; Kollmann C; Guan Y; Chou TC; Baroudy BM; Hirsch MS
    Antimicrob Agents Chemother; 2002 May; 46(5):1336-9. PubMed ID: 11959565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
    Strizki JM; Xu S; Wagner NE; Wojcik L; Liu J; Hou Y; Endres M; Palani A; Shapiro S; Clader JW; Greenlee WJ; Tagat JR; McCombie S; Cox K; Fawzi AB; Chou CC; Pugliese-Sivo C; Davies L; Moreno ME; Ho DD; Trkola A; Stoddart CA; Moore JP; Reyes GR; Baroudy BM
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12718-23. PubMed ID: 11606733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
    Ketas TJ; Klasse PJ; Spenlehauer C; Nesin M; Frank I; Pope M; Strizki JM; Reyes GR; Baroudy BM; Moore JP
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):177-86. PubMed ID: 12689409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.
    Tsamis F; Gavrilov S; Kajumo F; Seibert C; Kuhmann S; Ketas T; Trkola A; Palani A; Clader JW; Tagat JR; McCombie S; Baroudy B; Moore JP; Sakmar TP; Dragic T
    J Virol; 2003 May; 77(9):5201-8. PubMed ID: 12692222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.
    Billick E; Seibert C; Pugach P; Ketas T; Trkola A; Endres MJ; Murgolo NJ; Coates E; Reyes GR; Baroudy BM; Sakmar TP; Moore JP; Kuhmann SE
    J Virol; 2004 Apr; 78(8):4134-44. PubMed ID: 15047829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.
    Palani A; Shapiro S; Clader JW; Greenlee WJ; Blythin D; Cox K; Wagner NE; Strizki J; Baroudy BM; Dan N
    Bioorg Med Chem Lett; 2003 Feb; 13(4):705-8. PubMed ID: 12639563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.
    Pugach P; Ketas TJ; Michael E; Moore JP
    Virology; 2008 Aug; 377(2):401-7. PubMed ID: 18519143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
    Hazen RJ; Harvey RJ; St Clair MH; Ferris RG; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Romines KR; Chan JH; Boone LR
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4465-73. PubMed ID: 16251284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.
    Pugach P; Marozsan AJ; Ketas TJ; Landes EL; Moore JP; Kuhmann SE
    Virology; 2007 Apr; 361(1):212-28. PubMed ID: 17166540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
    Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.
    Princen K; Hatse S; Vermeire K; De Clercq E; Schols D
    Retrovirology; 2004 Mar; 1():2. PubMed ID: 15169555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
    Palani A; Shapiro S; Clader JW; Greenlee WJ; Cox K; Strizki J; Endres M; Baroudy BM
    J Med Chem; 2001 Oct; 44(21):3339-42. PubMed ID: 11585437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.
    Watson C; Jenkinson S; Kazmierski W; Kenakin T
    Mol Pharmacol; 2005 Apr; 67(4):1268-82. PubMed ID: 15644495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.